{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-097455","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.648681+00:00","generated_at":"2026-06-11T00:49:04.198323+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura receives $250k loan from majority owner, total debt $4.17M; warns operations may cease without further financing","bullets":["New $250k loan from Abuse Deterrent Pharma (66% owner) on Aug 30, 2023; total principal under note now $4,169,279.","Loan bears 5.25% interest, matures Dec 31, 2023; default rate 7.5%.","Proceeds only fund operations through mid-October 2023; company warns may scale back or cease operations without additional financing.","AD Pharma directly owns ~66% of common stock; its managing partner Mr. Schutte owns ~14% personally."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-097455","json":"https://secwatch.observer/filing/0001104659-23-097455.json","markdown":"https://secwatch.observer/filing/0001104659-23-097455.md","text":"https://secwatch.observer/filing/0001104659-23-097455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465923097455/0001104659-23-097455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465923097455/tm2325185d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:49:04.198323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d33d430b907e3f1779aa9b614d781ca46b20364d","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing December 31, 2023.","evidence_excerpt":"On August 30, 2023 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now totals $4,169,279, bears interest at 5.25% and matures on December 31, 2023, at which time all principal and interest is due.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465923097455/0001104659-23-097455-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$250,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}